Doripenem in the Treatment of Ventilator-Associated Pneumonia

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the clinical response rate of doripenem versus comparator in patients with ventilator-associated pneumonia (VAP).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Collaborator: Peninsula Pharmaceuticals, Inc.
• Treatments: Doripenem

Criteria

Inclusion Criteria:

• Patient has received mechanical ventilation for > 24 hours

• Presence of a new or progressive infiltrate on chest x-ray

Exclusion Criteria:

• Believed at study entry to have ventilator-associated pneumonia caused solely by pathogen(s) resistant to certain antibiotics

• History of moderate or severe hypersensitivity reactions to certain antibiotics